Posted by Michael Wonder on 10 Jul 2017
ABPI applies for Judicial Review over new procedures that restrict access to cost-effective medicines
10 July 2017 - Following a story published today in the Financial Times, the Association of the British Pharmaceutical Industry (ABPI) can confirm that it has applied for a Judicial Review.
The Judicial Review has been applied for over the introduction - by NICE - of an additional negotiation process for medicines that have already been assessed as cost-effective if they are likely to cost the NHS more than £20 million in any of the first three years of use. NICE’s own analysis shows that around one in five new medicines will be impacted.
The ABPI is also seeking to reverse changes to the assessment of medicines for very rare diseases, which we believe to be inappropriate and unworkable.
